
Background: N-acetylglutamate synthase deficiency (NAGSD) is the rarest urea cycle disorder and a potentially treatable cause of neonatal hyperammonemia. Because it may not be detected by routine newborn screening, delayed diagnosis can result in irreversible neurological injury. Objective: To describe the clinical, biochemical, and molecular findings of two related patients with NAGSD and to highlight the importance of early recognition and treatment. Methods: We report two related patients with clinically and molecularly confirmed NAGSD. Clinical presentation, biochemical results, neuroimaging, genetic findings, and treatment outcomes were reviewed. Results: Both patients presented in the neonatal period with hyperammonemia and later developed recurrent metabolic decompensation and seizures. Biochemical evaluation showed elevated glutamine with normal citrulline and normal acylcarnitine profiles, making early biochemical recognition challenging. Whole exome sequencing identified a homozygous pathogenic splice-site variant in the NAGS gene, c.427-2A>T, in both patients. Despite treatment with carglumic acid and dietary management, both developed significant neurodevelopmental delay, likely secondary to early hyperammonemic brain injury. Neuroimaging findings were consistent with metabolic encephalopathy. After diagnosis and treatment, no further hyperammonemic crises were reported. Conclusion: NAGSD should be considered in any neonate with unexplained hyperammonemia, even when newborn screening and citrulline levels are normal. Early empirical treatment with carglumic acid may be life-saving and can reduce the risk of permanent neurological damage, especially in high-consanguinity populations.
RNA-binding proteins are essential regulators of post-transcriptional gene expression, controlling RNA splicing, transport, localization, stability, and translation within the nervous system. Dysregulation of RNA–protein interaction networks has emerged as a critical mechanism underlying multiple neurogenetic and neurodegenerative disorders. Crosslinking and Immunoprecipitation technologies, including High-Throughput Sequencing Crosslinking and Immunoprecipitation, Photoactivatable-Ribonucleoside-Enhanced Crosslinking and Immunoprecipitation, Individual-Nucleotide Resolution Crosslinking and Immunoprecipitation, and Enhanced Crosslinking and Immunoprecipitation, have significantly advanced the ability to identify transcriptome-wide RNA-binding protein interaction sites with high specificity and resolution. These methodologies have enabled detailed characterization of RNA regulatory networks involved in neuronal homeostasis, synaptic plasticity, neurodegeneration, and tumor progression. This narrative review summarizes the principles and major variants of Crosslinking and Immunoprecipitation technologies and discusses their applications in neurogenetic disorders, including amyotrophic lateral sclerosis, Fragile X syndrome, Alzheimer’s disease, and neuroblastoma. Furthermore, the review highlights current technical limitations, analytical challenges, and future perspectives involving single-cell transcriptomics, multi-omics integration, artificial intelligence, and RNA-targeted therapeutic development. Collectively, Crosslinking and Immunoprecipitation-based methodologies represent powerful tools for elucidating disease-associated RNA regulatory mechanisms and may contribute to the identification of novel biomarkers and therapeutic targets in neurological and neuro-oncological diseases.
Background: Diamond–Blackfan anemia (DBA) is a rare inherited bone marrow failure syndrome characterized by pure red cell aplasia and is commonly caused by variants in ribosomal protein genes. Variants in RPS26 are relatively uncommon, and splice-site changes in this gene are still underreported. Case Presentation: We describe a 17-month-old female who presented with severe anemia with clinical features suggestive of Diamond–Blackfan anemia. Whole Exome sequencing (WES) identified a novel heterozygous de novo canonical splice-site variant, NM_001029.5:c.182-1G>A in the RPS26 gene. The variant was absent from population databases, including gnomAD, and was also confirmed by Sanger sequencing. In silico analysis using SpliceAI predicted disruption of the canonical splice acceptor site along with activation of a cryptic splice site, suggesting a deleterious effect on normal splicing. However, RNA studies are needed to confirm the exact splicing outcome and to better understand how this variant affects RPS26 function. Based on ACMG/AMP guidelines, the variant was classified as likely pathogenic. Conclusion: This case contributes to the known mutational spectrum of RPS26 and highlights the value of exome sequencing in the molecular evaluation of patients with suspected DBA.
Consanguineous marriages, defined as unions between biologically related individuals, are associated with an increased risk of autosomal recessive genetic disorders because relatives are more likely to share deleterious alleles inherited from a common ancestor. In contrast, Gotra exogamy in Hindu societies is a socio-cultural practice that discourages marriage within the same paternal lineage, whereas endogamy refers to marriage within a defined social or population group. Although Gotra exogamy may have historically limited certain forms of relatedness, its genetic implications remain indirect and culturally interpreted rather than scientifically established. Population genetic studies in India indicate that consanguinity and long-standing endogamy contribute to an increased prevalence of inherited disorders, estimated at 25–60 per 1000 births in some communities, depending on regional, socioeconomic, and cultural factors. These risks are primarily attributable to autosomal recessive inheritance resulting from increased carrier overlap among related individuals. This narrative review examines the relationships among Gotra exogamy, consanguinity, endogamy, and genetic disease risk from sociocultural, genetic, and public health perspectives through a structured review of published literature. The review highlights the importance of culturally sensitive genetic counseling, carrier screening, and community awareness programs in identifying at-risk families and reducing the burden of inherited disorders while respecting cultural traditions and promoting scientific literacy.
Background: Recurrent fetal loss can arise from a wide range of genetic abnormalities, many of which remain undetected in the absence of comprehensive molecular testing. Trio-based clinical exome sequencing enables the systematic identification of candidate mutations and variants of uncertain significance (VUS) that underlie fetal loss and supports accurate diagnosis and informed genetic counselling for affected families. Methods: Genomic DNA was extracted from fetal tissue and peripheral blood leukocytes of the couple, siblings, and grandparents. Trio-clinical exome sequencing was performed, followed by Sanger sequencing to confirm candidate variants. The variants were evaluated for pathogenicity and the pattern of inheritance. Results: Trio-clinical exome sequencing identified two homozygous nonsynonymous variants in the NEB gene, one in exon 6 (NM_001164507.2: c.367C>T; p.Arg123Cys) and another in exon 133 (NM_001164507.2: c.20279A>G; p.Asp6760Gly) in the proband. In addition, a hemizygous nonsynonymous variant in exon 10 of the X-linked OFD1 gene (NM_003611.3: c.1035G>T; p.Lys345Asn) and a homozygous nonsynonymous variant in exon 8 of the SLCO2A1 gene (NM_005630.3: c.1105G>T; p.Gly369Cys) were observed in the proband. The NEB and SLCO2A1 variants were heterozygous in the couple, and only the mother was heterozygous for the OFD1 variant. Conclusion: This study identified two candidate NEB gene variants (classified as variants of uncertain significance, VUS) as the most likely candidate contributors to recurrent fetal loss. The findings provide the basis for informed genetic counselling and reproductive risk assessment.